Literature DB >> 2209383

Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP).

E A Palmer1.   

Abstract

Twenty-three centers collaborated in this prospectively designed study involving infants born weighing less than 1251 grams. Patients examinations began 4 to 6 weeks from birth. For entry into the study, two investigators had to agree that an eye had developed stage 3 ROP involving a threshold number of at least 5 contiguous or 8 total clock hour sectors of zone 1 or 2, and 'plus' disease to a degree specified by a standard photograph. Cryotherapy was lightly applied to the avascular zone between the ridge of ROP and the ora serrata, in an average of about 50 separate spots. Outcome was determined 3 and 12 months following randomization, by means of masked readings of fundus photographs. Preliminary results were published in the Archives of Ophthalmology, Vol. 106, pp. 471-479, 1988. In these results from 172 of the 291 study patients, 43.0% of the control eyes had an adverse outcome (defined as retinal detachment, macular fold, or retrolental mass), as compared to 21.8% adverse outcome for eyes that received cryotherapy.

Entities:  

Mesh:

Year:  1990        PMID: 2209383     DOI: 10.1007/bf02482615

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  14 in total

1.  Pregnancy disorders appear to modify the risk for retinopathy of prematurity associated with neonatal hyperoxemia and bacteremia.

Authors:  Jennifer W Lee; Thomas McElrath; Minghua Chen; David K Wallace; Elizabeth N Allred; Alan Leviton; Olaf Dammann
Journal:  J Matern Fetal Neonatal Med       Date:  2013-02-14

2.  Prevalence of retinopathy of prematurity in Brunei Darussalam.

Authors:  Nadir Ali Mohamed Ali; Joshua George; Nayan Joshi; Elizabeth Chong
Journal:  Int J Ophthalmol       Date:  2013-06-18       Impact factor: 1.779

3.  Characteristic clinical features associated with aggressive posterior retinopathy of prematurity.

Authors:  Y J Ahn; K E Hong; H R Yum; J H Lee; K S Kim; Y A Youn; S H Park
Journal:  Eye (Lond)       Date:  2017-02-24       Impact factor: 3.775

4.  A physiologic reduced oxygen protocol decreases the incidence of threshold retinopathy of prematurity.

Authors:  Kenneth W Wright; David Sami; Lisa Thompson; Rangasamy Ramanathan; Roy Joseph; Sonal Farzavandi
Journal:  Trans Am Ophthalmol Soc       Date:  2006

5.  Risk factors for retinopathy of prematurity: insights from outlier infants.

Authors:  Alexander D Port; R V Paul Chan; Susan Ostmo; Dongseok Choi; Michael F Chiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-07-23       Impact factor: 3.117

6.  The results of intravitreal bevacizumab monotherapy for treating aggressive posterior retinopathy of prematurity and Type 1 retinopathy of prematurity.

Authors:  Ayşegül Çömez; Yalçın Karaküçük; Mehmet Cüneyt Özmen; Pelin Çelemler; Oğuzhan Saygılı
Journal:  Eye (Lond)       Date:  2021-01-29       Impact factor: 3.775

7.  Asymmetric Outcomes of Type 1 Retinopathy of Prematurity after Bilateral Intravitreal Ranibizumab Treatment.

Authors:  Qiujing Huang; Qi Zhang; Yu Xu; Xunda Ji; Ping Fei; Jie Peng; Yi-An Li; Peiquan Zhao
Journal:  J Ophthalmol       Date:  2017-03-29       Impact factor: 1.909

8.  Wide-field digital imaging based telemedicine for screening for acute retinopathy of prematurity (ROP). Six-year results of a multicentre field study.

Authors:  Birgit Lorenz; Katerina Spasovska; Heike Elflein; Nico Schneider
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-05-22       Impact factor: 3.117

9.  The genetics of retinopathy of prematurity: a model for neovascular retinal disease.

Authors:  Ryan Swan; Sang Jin Kim; J Peter Campbell; R V Paul Chan; Kemal Sonmez; Kent D Taylor; Xiaohui Li; Yii-Der Ida Chen; Jerome I Rotter; Charles Simmons; Michael F Chiang
Journal:  Ophthalmol Retina       Date:  2018-03-08

10.  Retinopathy of prematurity screening in the Indian population: it's time to set our own guidelines!

Authors:  Vasumathy Vedantham
Journal:  Indian J Ophthalmol       Date:  2007 Sep-Oct       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.